Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLMartin Reck, Christian Manegold, Natasha B. Leighl et al.|Journal of Clinical Oncology|2009Cited by 1.5k
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Martin Reck, C. Manegold, Joachim von Pawel et al.|Annals of Oncology|2010Cited by 644
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung CancerJoachim von Pawel, Markus F. Renschler, Robert M. Jotte et al.|Journal of Clinical Oncology|2014Cited by 344